TSE.4540
Supplementary Materials
The First Quarter of the Term Ending March 31, 2024
August 3, 2023
TSUMURA & CO.
Consolidated Statements of Income ・・・・・ | 1 | |
investments, R&D expenses, etc. ・・・・・ | 1 | |
Product sales | ・・・・・ | 2 |
Growth rates of 129 prescription Kampo products ・・・・・ | 2 | |
Consolidated Balance Sheets | ・・・・・ | 3 |
Consolidated Statements of Cash Flows ・・・・・ | 3 | |
Quarterly data | ||
Consolidated Statements of Income ・・・・・ | 4 | |
Consolidated Balance Sheets | ・・・・・ | 4 |
Consolidated Statements of Cash Flows ・・・・・ | 5 | |
Product sales | ・・・・・ | 5 |
Consolidated Statements of Income | (Million yen) | ||||||||||||||
FY 3/2023 1Q | FY 3/2024 1Q | Year-on-year | Forecast for 2Q (cumulative total) | Full-year forecast for FY 3/2024 | |||||||||||
Year-on- | Year-on-year | Year-on- | Year-on- | ||||||||||||
Amount | % of sales | Amount | % of sales | Amount | % | Amount | % of sales | year | Amount | % of sales | year | year | |||
(Amount) | (%) | (Amount) | (%) | ||||||||||||
Net sales | 34,417 | 100.0% | 37,036 | 100.0% | 2,618 | 7.6% | 74,000 | 100.0% | 3,892 | 5.6% | 150,500 | 100.0% | 10,456 | 7.5% | |
Domestic business | 31,562 | 92.9% | 32,988 | 89.1% | 1,426 | 4.5% | 65,900 | 89.1% | 2,985 | 4.7% | 133,300 | 88.6% | 8,601 | 6.9% | |
China business | 2,855 | 7.1% | 4,047 | 10.9% | 1,191 | 41.7% | 8,100 | 10.9% | 906 | 12.6% | 17,200 | 11.4% | 1,854 | 12.1% | |
Cost of sales | 16,462 | 47.8% | 20,341 | 54.9% | 3,879 | 23.6% | 39,600 | 53.5% | 4,302 | 12.2% | 83,000 | 55.1% | 11,237 | 15.7% | |
Gross profit on sales | 17,954 | 52.2% | 16,694 | 45.1% | (1,260) | (7.0)% | 34,400 | 46.5% | (409) | (1.2)% | 67,500 | 44.9% | (781) | (1.1)% | |
Selling, general and administrative expenses | 11,601 | 33.7% | 12,009 | 32.4% | 408 | 3.5% | 24,900 | 33.6% | 1,767 | 7.6% | 49,500 | 32.9% | 2,134 | 4.5% | |
Operating profit | 6,353 | 18.5% | 4,684 | 12.6% | (1,668) | (26.3)% | 9,500 | 12.8% | (2,177) | (18.6)% | 18,000 | 12.0% | (2,916) | (13.9)% | |
Domestic business | 6,404 | 18.6% | 4,684 | ー | (1,719) | (26.9)% | 9,900 | ー | (1,865) | (15.9)% | 18,400 | ー | (2,790) | (13.2)% | |
China business | (50) | (0.1)% | 0 | ー | 51 | ー | (400) | ー | (312) | ー | (400) | ー | (126) | ー | |
Ordinary profit | 8,665 | 25.2% | 5,989 | 16.2% | (2,676) | (30.9)% | 9,800 | 13.2% | (6,165) | (38.6)% | 18,600 | 12.4% | (4,853) | (20.7)% | |
Profit attributable to owners of parent | 6,632 | 19.3% | 4,332 | 11.7% | (2,300) | (34.7)% | 6,800 | 9.2% | (5,089) | (42.8)% | 13,000 | 8.6% | (3,482) | (21.1)% | |
Investments, R&D expenses, etc. | (Million yen) | ||||||||||||||
FY 3/2023 1Q | FY 3/2024 1Q | Year-on-year | Forecast for 2Q (cumulative total) | Full-year forecast for FY 3/2024 | |||||||||||
Year-on- | Year-on-year | Year-on- | Year-on- | ||||||||||||
Amount | % of sales | Amount | % of sales | Amount | % | Amount | % of sales | year | Amount | % of sales | year | year | |||
(Amount) | (%) | (Amount) | (%) | ||||||||||||
Investments | 2,251 | 6.5% | 3,889 | 10.5% | 1,637 | 72.7% | 11,000 | 14.9% | 4,265 | 63.3% | 33,500 | 22.3% | 18,820 | 128.2% | |
Capital investments | 2,037 | 5.9% | 2,660 | 7.2% | 623 | 30.6% | 9,500 | 12.8% | 4,748 | 100.0% | 29,500 | 19.6% | 18,327 | 164.0% | |
R&D expenses | 2,139 | 6.2% | 2,218 | 6.0% | 79 | 3.7% | 4,400 | 5.9% | 734 | 20.0% | 8,500 | 5.6% | 905 | 11.9% | |
Advertising expenses | 126 | 0.4% | 105 | 0.3% | (20) | (16.4)% | 400 | 0.5% | (7) | (1.8)% | 1,000 | 0.7% | (26) | (2.6)% | |
Depreciation | 2,456 | 7.1% | 2,454 | 6.6% | (1) | (0.1)% | 4,900 | 6.6% | (80) | (1.6)% | 10,200 | 6.8% | 98 | 1.0% | |
Personnel expenses | 8,355 | 24.3% | 8,898 | 24.0% | 542 | 6.5% | 18,500 | 25.0% | 1,641 | 9.7% | 36,800 | 24.5% | 2,555 | 7.5% | |
1
Product sales | (Million yen) | ||||||||||||
Rank | No. | Product Name | FY 3/2023 | FY 3/2024 | Year-on- | Year-on- | |||||||
1Q | 1Q | year | year | ||||||||||
1 | ☆ | 100 | Daikenchuto | 2,505 | 2,515 | 9 | 0.4% | ||||||
2 | ☆ | 54 | Yokukansan | 1,933 | 1,940 | 6 | 0.4% | ||||||
3 | G | 41 | Hochuekkito | 1,881 | 1,931 | 49 | 2.6% | ||||||
4 | ☆ | 43 | Rikkunshito | 1,860 | 1,861 | 1 | 0.1% | ||||||
5 | G | 17 | Goreisan | 1,542 | 1,801 | 259 | 16.8% | ||||||
6 | G | 24 | Kamishoyosan | 1,296 | 1,305 | 9 | 0.7% | ||||||
7 | 68 | Shakuyakukanzoto | 1,281 | 1,043 | (238) | (18.6)% | |||||||
8 | 62 | Bofutsusyosan | 794 | 1,001 | 206 | 26.0% | |||||||
9 | ☆ | 107 | Goshajinkigan | 932 | 995 | 62 | 6.7% | ||||||
10 | 29 | Bakumondoto | 805 | 878 | 72 | 9.0% | |||||||
17 | G | 137 | Kamikihito | 501 | 590 | 88 | 17.7% | ||||||
18 | G | 108 | Ningin'yoeito | 507 | 561 | 54 | 10.6% | ||||||
23 | ☆ | 14 | Hangeshashinto | 359 | 370 | 11 | 3.2% | ||||||
Total of "Drug Fostering" Program formulations | 7,591 | 7,683 | 92 | 1.2% | |||||||||
Total of Growing formulations | 5,730 | 6,191 | 461 | 8.0% | |||||||||
Total of 129 prescription Kampo products | 30,277 | 31,838 | 1,560 | 5.2% | |||||||||
☆ :"Drug Fostering" Program formulations | G:Growing formulations | ||||||||||||
Growth rates of 129 prescription Kampo products | |||||||||||||
FY 3/2019 | FY 3/2020 | FY 3/2021 | FY 3/2022 | FY 3/2023 | FY 3/2024 | ||||||||
1Q | |||||||||||||
Amount | 2.7% | 1.8% | 1.1% | 8.1% | 4.6% | 5.2% | |||||||
Number of items with higher yen sales | 83 | 66 | 82 | 110 | 98 | 90 | |||||||
2
Consolidated Balance Sheets | (Million yen) | ||
As of March 31 | As of June 30 | Increase / | |
2023 | 2023 | decrease | |
Total assets | 396,813 | 405,437 | 8,623 |
Current assets | 268,320 | 272,369 | 4,048 |
Liquid assets | 152,839 | 150,589 | (2,250) |
Inventories | 101,726 | 107,501 | 5,774 |
Non-current assets | 128,492 | 133,067 | 4,574 |
Property, plant and equipment | 93,415 | 94,530 | 1,114 |
Total liabilities | 124,566 | 126,345 | 1,779 |
Current liabilities | 47,205 | 49,402 | 2,197 |
Non-current liabilities | 77,361 | 76,943 | (418) |
Total net assets | 272,246 | 279,091 | 6,844 |
Consolidated Statements of Cash Flows | (Million yen) | ||
FY 3/2023 | FY 3/2024 | Year-on-year | |
1Q | 1Q | ||
Cash flows from operating activities | 4,785 | (152) | (4,937) |
Cash flows from investing activities | (4,145) | (4,906) | (760) |
Cash flows from financing activities | (2,418) | (1,579) | 839 |
Cash and cash equivalents at the end of the quarter | 68,022 | 88,917 | 20,894 |
3
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Tsumura & Co. published this content on 03 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 August 2023 07:31:20 UTC.